Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04091984 · ClinicalTrials.gov registry record
The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)
A clinical trial of Kidney Transplant Rejection, sponsored by Natera.
- Active
- Registry status
- 5,000
- Enrollment target
- 20
- Study locations
NCT04091984 is a study of Kidney Transplant Rejection that is active but no longer recruiting, run by Natera. The registered enrollment target is 5,000 participants, above the 180-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (2678% higher). The trial reports 20 study locations across 8 states.
The verdict
NCT04091984, a study of Kidney Transplant Rejection, is active but no longer recruiting, sponsored by Natera.
- ACTIVE NOT RECRUITING
- Registry status
- 5,000 participants
- Enrollment target
- 20
- Study locations
Study Summary
The ProActive registry is a longitudinal, multi-center study with a prospective arm observing clinical care for patients receiving physician ordered Prospera, an allograft rejection test, and a historical control arm collecting data on cases at the same sites whose kidney allograft rejection status was managed with Serum Creatinine SCr/estimated Glomerular Filtration Rate eGFR. This registry will compare patient management and outcomes in patients who receive Prospera (Prospera arm) to the outcomes of the historical control group (control arm) to determine Prospera's clinical utility. High-risk subjects defined as having a biopsy-demonstrated rejection event or at least one pre-existing Donor Specific Antibody DSA with total Mean Fluorescent Intensity MFI\>3000 or a calculated Panel Reactive Antibodies cPRA\>70% will be followed for an additional period up to 24 months in both the Prospera arm and historical control arm.
Conditions Studied
Interventions
- DIAGNOSTIC_TEST Prospera
Study Locations (20)
California
- University of California Davis Medical Center - Davis
- University of California, Irvine - Irvine
- Keck School of Medicine USC - Los Angeles
- The Regents of the University of California on behalf of its Los Angeles campus - Los Angeles
- Riverside Community Hospital - Riverside
- California Institute of Renal Research - San Diego
Arizona
- Arizona Kidney Disease & Hypertension Centers - Phoenix
- Arizona Kidney Disease & Hypertension Centers - Scottsdale
- Arizona Kidney Disease and Hypertension Centers - Tucson
- Arizona Kidney Disease & Hypertension Centers - Tucson
- Banner University Medical Center - Tucson
Florida
- University of Florida - Gainesville
- Florida Health Sciences Center - Tampa
- Cleveland Clinic Florida (Weston) - Weston
Connecticut
- Hartford Hospital - Hartford
- Yale University, School of Medicine - New Haven
Alabama
- University of Alabama at Birmingham - Birmingham
Colorado
- University of Colorado - Aurora
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Illinois
- Loyola University Medical Center - Maywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5,000 participants |
| Start Date | 2019-11-06 |
| Est. Completion | 2027-10-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04091984
The ClinicalTrials.gov registry entry for NCT04091984 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 5,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 180-participant average among 8 other Kidney Transplant Rejection trials with a reported enrollment target (2678% higher). The listed sponsor is Natera, which has 27 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Kidney Transplant Rejection appearing as the primary indexed condition, and to 1 intervention - of which Prospera is the first listed.
NCT04091984 reports 20 study locations spanning 8 distinct geographic areas - top geographies include California, Arizona, Florida.
Frequently Asked Questions
What is clinical trial NCT04091984 about?
NCT04091984 is a clinical study titled "The PROspera Kidney Transplant ACTIVE Rejection Assessment Registry (ProActive)". The ProActive registry is a longitudinal, multi-center study with a prospective arm observing clinical care for patients receiving physician ordered Prospera, an allograft rejection test, and a historical control arm collecting data on cases at the same sites whose kidney allograft rejection status ...
What is the current status of trial NCT04091984?
This trial is currently active not recruiting. The enrollment target is 5,000 participants. The study started on 2019-11-06. Estimated completion is 2027-10-01.
What conditions does trial NCT04091984 study?
This clinical trial studies the following conditions: Kidney Transplant Rejection.
What interventions are being tested in trial NCT04091984?
The interventions under investigation include: Prospera (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04091984?
This trial is sponsored by Natera, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04091984 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Transplant Rejection
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Trifecta-Kidney cfDNA-MMDx Study
RECRUITING
-
Validation of Donor-Derived Cell-Free DNA (Dd-cfDNA) for Kidney Transplant Monitoring
RECRUITING
-
Evaluating Urinary CXCL10 for Enhanced Detection of Acute Rejection in Kidney Transplant Patients With Low DD-CFDNA
RECRUITING
-
Microbiome and Immunosuppression: The Mission Study
ACTIVE NOT RECRUITING
-
Validation of Genomic Immune-phenotyping Profiles to Predict Risk of Kidney Transplant Rejection
ACTIVE NOT RECRUITING
-
Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection
ACTIVE NOT RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.